Karyopharm Therapeutics News

Buy Rating for Karyopharm Therapeutics: Debt Restructuring and Promising Xpovio Studies Drive Optimistic Outlook

TipRanksMay 10 13:41

HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $8 Price Target

HC Wainwright & Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and maintains $8 price target.

BenzingaMay 9 18:53

Karyopharm Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 684.31% HC Wainwright & Co. → $8 Reiterates Buy → Buy 03/01/2024 684.31% HC Wainwright & Co. $1

BenzingaMay 9 18:52

Optimistic Buy Rating for Karyopharm Therapeutics Amidst Financial Stability and Promising Clinical Trials

TipRanksMay 9 18:27

Karyopharm Therapeutics (KPTI) Gets a Buy From Barclays

TipRanksMay 9 15:26

Karyopharm Therapeutics Inc (KPTI) Q1 2024 Earnings Call Transcript Highlights: Navigating ...

Yahoo FinanceMay 9 15:02

Karyopharm Therapeutics | 10-Q: Quarterly report

Futu NewsMay 9 05:18 · Announcements

Karyopharm Announces Significant Refinancing Transactions

Seeking AlphaMay 8 23:06

Karyopharm Therapeutics Reports Q1 2024 Financial Results: A Detailed Review

Yahoo FinanceMay 8 21:12

Karyopharm Therapeutics Inc. Q1 Loss Increases, but Beats Estimates

RTTNewsMay 8 20:34

Karyopharm Therapeutics Enhances Financial Stability and Liquidity

TipRanksMay 8 20:02

Karyopharm Announces Refinancing Transactions $148M Of Existing Convertible Notes Due In 2025 To Be Exchanged for $111M Of New Convertible Notes Due In 2029 And Warrants, Issues New $100M Senior Secured Term Loan Due in 2028a

Karyopharm Announces Refinancing Transactions $148M Of Existing Convertible Notes Due In 2025 To Be Exchanged for $111M Of New Convertible Notes Due In 2029 And Warrants, Issues New $100M Senior Secur

BenzingaMay 8 19:39

Karyopharm Therapeutics Reaffirms 2024 Revenue Guidance Of $140M-$160M Versus Consensus Of $146.52M, Including U.S. XPOVIO Net Product Revenue Guidance of $100M-$120M

Karyopharm Therapeutics Reaffirms 2024 Revenue Guidance Of $140M-$160M Versus Consensus Of $146.52M, Including U.S. XPOVIO Net Product Revenue Guidance of $100M-$120M

BenzingaMay 8 19:39

Karyopharm Therapeutics Q1 2024 GAAP EPS $(0.32) Beats $(0.33) Estimate, Sales $33.126M Miss $34.473M Estimate

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.33) by 3.03 percent. This is a 6.67 percent decrease over losses o

BenzingaMay 8 19:38

Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Reports Q1 Revenue $33.1M, Vs. Street Est of $34.5M

07:37 AM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Reports Q1 Revenue $33.1M, vs. Street Est of $34.5M

MT NewswiresMay 8 19:37

Karyopharm Therapeutics Still Sees 2024 U.S. Xpovio Net Product Revenue $100M-$120M >KPTI

Karyopharm Therapeutics Still Sees 2024 U.S. Xpovio Net Product Revenue $100M-$120M >KPTI

Dow JonesMay 8 19:33

Karyopharm Therapeutics Backs 2024 View of Rev $140M-$160M >KPTI

Karyopharm Therapeutics Backs 2024 View of Rev $140M-$160M >KPTI

Dow JonesMay 8 19:32

Karyopharm Therapeutics 1Q Loss $37.4M >KPTI

Karyopharm Therapeutics 1Q Loss $37.4M >KPTI

Dow JonesMay 8 19:30

Karyopharm Therapeutics 1Q Loss/Shr 32c >KPTI

Karyopharm Therapeutics 1Q Loss/Shr 32c >KPTI

Dow JonesMay 8 19:30

Karyopharm Therapeutics 1Q Rev $33.1M >KPTI

Karyopharm Therapeutics 1Q Rev $33.1M >KPTI

Dow JonesMay 8 19:30